Midodrine ( DrugBank: Midodrine )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
17	多系統萎縮症	3
58	肥大型心筋症	1

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04620382 (ClinicalTrials.gov)	November 9, 2020	27/10/2020	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease	Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression	Vanderbilt University Medical Center	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	40 Years	80 Years	All	31	Early Phase 1	United States
2	NCT02897063 (ClinicalTrials.gov)	September 2016	7/9/2016	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2	Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension	Drug: Droxidopa;Drug: Midodrine;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	34	Phase 1	United States
3	NCT02365012 (ClinicalTrials.gov)	April 2014	10/2/2015	Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine	Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine	Orthostatic Intolerance;Parkinson's Disease	Drug: Midodrine	Philadelphia Veterans Affairs Medical Center	NULL	Recruiting	22 Years	89 Years	Both	50	N/A	United States

17. 多系統萎縮症

---

臨床試験数 : 119 /  薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04782830 (ClinicalTrials.gov)	February 5, 2021	1/3/2021	Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms	Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms	Orthostatic; Hypotension, Neurogenic;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy; Hypotension, Parkinsonism	Device: Accelerometer;Drug: placebo pill;Drug: Midodrine or atomoxetine pill	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	29	N/A	United States
2	NCT04620382 (ClinicalTrials.gov)	November 9, 2020	27/10/2020	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease	Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression	Vanderbilt University Medical Center	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	40 Years	80 Years	All	31	Early Phase 1	United States
3	NCT02897063 (ClinicalTrials.gov)	September 2016	7/9/2016	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2	Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension	Drug: Droxidopa;Drug: Midodrine;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	34	Phase 1	United States

58. 肥大型心筋症

---

臨床試験数 : 126 /  薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003521-34-FR (EUCTR)	09/10/2015	08/09/2015	Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine	Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine - Light-CARMIDO	Hypertrophic cardiomyopathy;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Gutron 2,5mg INN or Proposed INN: MIDODRINE HYDROCHLORIDE Trade Name: Gutron 5mg INN or Proposed INN: MIDODRINE HYDROCHLORIDE	CHU de Bordeaux	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France

先頭へ